^
    Back
    Association details:
    Biomarker:CXCR4 S338X + TP53 R196X
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Ninlaro (ixazomib) (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood Adv
    Title:

    Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

    Published date:
    08/21/2020
    Excerpt:
    One of the patients with a nonsense CXCR4 S338X mutation also harbored a TP53 R196X mutation…TTR and TTMR were 6 and 14 months, respectively. At best response, the patient attained PR. As of last follow-up visit, the patient had not yet progressed, for a PFS of 47 months.
    DOI:
    https://doi.org/10.1182/bloodadvances.2020001963